Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | Biomarker-directed BISCAY data: durvalumab plus targeted therapies in mUC

Thomas Powles • 28 Sep 2019
ESMO 2019
Bladder Cancer Genitourinary Cancer Durvalumab Olaparib
BISCAY

BISCAY (NCT02546661) is an open-label, randomized, biomarker-directed, phase 1b study of durvalumab in combination with targeted therapies in metastatic urothelial cancer. Here, Principal Investigator Thomas Powles, MBBS, MRCP, MD, Barts Cancer Institute, London, UK, discusses the data presented at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Thomas Powles

2:04
Unmet educational needs in GU cancers
Thomas Powles • 16 Feb 2023
2:37
Key unmet needs in kidney cancer
Thomas Powles • 16 Feb 2023
1:44
Highlights in renal cell carcinoma from ASCO GU 2023 and what to look out for in the future
Thomas Powles • 23 Feb 2023
4:01
COSMIC-313: cabo + nivo + ipi in 1L advanced RCC of IMDC intermediate or poor risk
Thomas Powles • 16 Feb 2023

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals